Adverse events in the treatment of multidrug-resistant tuberculosis: results from the DOTS-Plus initiative.

Eva Nathanson, Rajesh Gupta, Pedro Leonardo Tito Huamaní, Vaira Leimane, Alexander Pasechnikov, Thelma E. Tupasi, Koen Vink, E. Jaramillo, M A Espinal

PubMed · 2004 · 189 citations · 7 references

Concepts

Abstract

Adverse events associated with second-line drugs have been mentioned as obstacles in the management of multidrug-resistant tuberculosis (MDR-TB). Data on adverse events were collected from five DOTS-Plus sites in Estonia, Latvia, Peru (Lima), the Philippines (Manila) and the Russian Federation (Tomsk Oblast). The results show that among 818 patients enrolled on MDR-TB treatment only 2% of patients stopped treatment, but 30% required removal of the suspected drug(s) from the regimen due to adverse events. The study shows that adverse events are manageable in the treatment of MDR-TB in resource-limited settings provided that standard management strategies are applied.

References

7